Owens & Minor Inc. (NYSE:OMI) reported first-quarter 2025 adjusted EPS of 23 cents, up from 19 cents a year ago, beating the consensus of 20 cents.
The company reported sales of $2.63 billion, which were almost flat year over year and missed the consensus of $2.66 billion.
Products & Healthcare Services revenue of $1.96 billion, down 1%. Patient Direct revenue of $673.8 million, up 6% year-over-year.
In February, the company said Citi would serve as its exclusive financial advisor regarding the potential sale of the Products & Healthcare Services segment.
Also Read: Cardinal Health Lifts FY25 EPS Outlook, Sees Growth Despite Tariff Risks
The company reported adjusted operating income of $61.3 million, up from $57.4 million. Adjusted EBITDA increased from $116.3 million to $121.9 million.
The Products & Healthcare Services segment saw top-line growth in medical distribution, according to CEO Edward Pesicka.
“We remain actively engaged in the sale process of our Products & Healthcare Services segment," he added.
Pesicka concluded, "Looking ahead, our focus remains on disciplined capital deployment, working towards our leverage target, successfully navigating potential changes in government policy, including tariffs and integrating our planned acquisition of Rotech. We remain bullish on the outlook for our Patient Direct segment and the strengthening of our P&HS businesses."
Guidance: Owens & Minor reaffirmed fiscal 2025 adjusted earnings per share guidance of $1.60-$1.85 versus the consensus of $1.67.
The company forecasts 2025 sales of $10.85 billion-$11.15 billion compared to the consensus of $11.05 billion.
The company's outlook for 2025 excludes any impact of the previously announced Rotech acquisition, the Products & Healthcare Services segment, or tariffs.
The healthcare logistics company expects adjusted EBITDA for 2025 to be $560 million to $590 million.
Price Action: Owens & Minor’s stock is down 7.86% at $7.15 at the last check Friday.
Read Next:
Image: Shutterstock
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。